MedTrace Logo

Imaging Histone Deacetylase in the Heart

NCT03549559 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2025-12-22

No results posted yet for this study

Summary

The overall goal of this PET-MR imaging trial is to evaluate 11C-Martinostat, a histone deacetylase targeted radioligand, in patients with aortic stenosis, individuals with diabetes, and healthy volunteers.

Conditions

  • Heart Failure With Normal Ejection Fraction
  • Left Ventricular Hypertrophy
  • Aortic Valve Stenosis
  • Diabetes

Interventions

DRUG

11C-Martinostat

Imaging probe for evaluating the activity of histone deacetylase in the heart

DEVICE

PET-MRI

Siemens PET-MR Scanner (Biograph MMR)

Sponsors & Collaborators

  • Massachusetts General Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-07
Primary Completion
2026-03-01
Completion
2026-09-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03549559 on ClinicalTrials.gov